Azumolene

CAS No. 64748-79-4

Azumolene( EU4093 free base )

Catalog No. M22989 CAS No. 64748-79-4

Azumolene1.EU4093 (azumolene sodium) is a direct acting, skeletal muscle relaxant with structural similarities to dantrolene sodium in that the para-nitro phenyl group of dantrolene sodium is replaced by a para-bromo phenyl group. 2. The effect of EU4093 on the twitch of the intact rat soleus preparation is nearly maximal at a dose of 20 mg kg-1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 71 In Stock
2MG 40 In Stock
5MG 64 In Stock
10MG 112 In Stock
25MG 235 In Stock
50MG 365 In Stock
100MG 551 In Stock
200MG Get Quote In Stock
500MG 1190 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Azumolene
  • Note
    Research use only, not for human use.
  • Brief Description
    Azumolene1.EU4093 (azumolene sodium) is a direct acting, skeletal muscle relaxant with structural similarities to dantrolene sodium in that the para-nitro phenyl group of dantrolene sodium is replaced by a para-bromo phenyl group. 2. The effect of EU4093 on the twitch of the intact rat soleus preparation is nearly maximal at a dose of 20 mg kg-1.
  • Description
    Azumolene1.EU4093 (azumolene sodium) is a direct acting, skeletal muscle relaxant with structural similarities to dantrolene sodium in that the para-nitro phenyl group of dantrolene sodium is replaced by a para-bromo phenyl group. 2. The effect of EU4093 on the twitch of the intact rat soleus preparation is nearly maximal at a dose of 20 mg kg-1. This dose of EU4093 reduces the amplitude of the twitch to 31.9% of the control value. By comparison, dantrolene sodium reduced the twitch amplitude to 31.3% of the control value at a dose of 5 mg kg-1. 3. The contraction of intrafusal muscle as measured by the response of spindle afferent discharge was also reduced by EU4093. 4. The most significant difference between the effect of EU4093 and dantrolene sodium on the contraction of intrafusal muscle was that EU4093 had an appreciable depressant action at high stimulation frequencies at which dantrolene sodium had only a minimal relaxant effect on the intrafusal muscle contraction.
  • In Vitro
    Pretreatment with 20 μM Azumolene for 1-2 min inhibits SOCE activated by subsequent addition of caffeine and ryanodine to promote RyR-dependent sarcoplasmic reticulum Ca2+ store depletion in mouse myotubes and adult muscle fibers.
  • In Vivo
    The effect of Azumolene (EU4093) on the twitch of the intact rat soleus preparation is nearly maximal at a dose of 20 mg/kg. This dose of Azumolene reduces the amplitude of the twitch to 31.9% of the control value. The contraction of intrafusal muscle as measured by the response of spindle afferent discharge is also reduced by Azumolene.
  • Synonyms
    EU4093 free base
  • Pathway
    GPCR/G Protein
  • Target
    Calcium Channel
  • Recptor
    Calcium Channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    64748-79-4
  • Formula Weight
    349.14
  • Molecular Formula
    C13H9BrN4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:13.89 mg/mL (39.78 mM; Need ultrasonic)
  • SMILES
    O=C1NC(CN1/N=C/C2=NC=C(C3=CC=C(Br)C=C3)O2)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • DS16570511

    DS16570511 is a cellular osmotic inhibitor of mitochondrial calcium monoab, which blocks MCU or MICU1-dependent Ca2+ influx.DS16570511 dose - dependent inhibition of serum-induced mitochondrial Ca2+ influx in HEK293A cells with IC50 of 7 M.DS16570511 inhibits the uptake of isolated Ca2+. mitochondria from human cells, rat heart and pig heart.

  • Stugeron

    Cinnarizine is a drug derivative of piperazine, and characterized as an antihistamine and a calcium channel blocker.

  • Ziconotide Acetate ...

    Ziconotide is an analgesic agent and has been used to treat neuropathic and non-neuropathic pain. Ziconotide acts by binding to N-type calcium channels situated on the terminal part of primary afferent neurons of the nociceptive pathway therefore reducing synaptic transmission with potent antinociceptive effects.